Integrated Multi-Omics Profiling Identifies an Immunotherapy Vulnerable and Prognostic Associated Subtype in Cholangiocarcinoma [0.03%]
Lu Chen,Yuchao He,Hong Su et al.
Lu Chen et al.
Introduction: Cholangiocarcinoma (CCA) is an aggressive malignancy with poor prognosis and limited treatment options. Molecular heterogeneity and the tumor immune microenvironment play crucial roles in CCA progression and...
Oncological Outcomes and Treatment Strategies for Borderline Resectable Hepatocellular Carcinoma Based on the Oncological Resectability Classification [0.03%]
Takashi Hamada,Akihiko Soyama,Hajime Matsushima et al.
Takashi Hamada et al.
Background: Although hepatic resection is the most effective curative treatment for hepatocellular carcinoma (HCC) in selected patients, survival outcomes can vary significantly depending on tumor burden and biology. To p...
Comparative Efficacy of Initial Treatment Strategies in Patients with Transarterial Chemoembolisation-Unsuitable Hepatocellular Carcinoma [0.03%]
不适合进行经动脉化疗栓塞治疗的肝细胞癌患者初始治疗策略的效果比较
Edoardo G Giannini,Andrea Pasta,Giulia Pieri et al.
Edoardo G Giannini et al.
Introduction: Transarterial chemoembolisation (TACE) is considered the standard-of-care for patients with intermediate-stage hepatocellular carcinoma (HCC), despite several patients exhibit features that may be associated...
Gd-EOB-DTPA-Enhanced Magnetic Resonance Imaging for Predicting Immunotherapy Response in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis [0.03%]
超顺磁性氧化铁肝细胞癌免疫治疗反应的预测：系统回顾和meta分析
Wenbo Xie,Linmao Sun,Yumin Fu et al.
Wenbo Xie et al.
Introduction: Hepatocellular carcinoma (HCC) harboring CTNNB1 mutations that activate the Wnt/β-catenin pathway demonstrates increased gadoxetic acid (Gd-EOB-DTPA) uptake due to overexpressed organic anion transporting p...
Review
Liver cancer. 2026 Feb 19. DOI:10.1159/000550938 2026
Age-Adjusted Charlson Comorbidity Index Guides Risk Stratification for Hepatocellular Carcinoma Patients Treated with TACE Combined with Immune Checkpoint Inhibitors and Targeted Therapy: A Multicenter Retrospective Cohort Study [0.03%]
基于TACE联合免疫检查点抑制剂和靶向治疗的肝细胞癌患者的危险分层需调整年龄的Charlson合并症指数指导作用：一项多中心回顾性队列研究
Xiaohan Lin,Shiying Zhang,Meiching Ong et al.
Xiaohan Lin et al.
Background: Hepatocellular carcinoma (HCC) imposes a substantial global burden. Triple therapy including transarterial chemoembolization, immune checkpoint inhibitors, and targeted therapy offers survival benefits but inc...
Survival Outcomes, Recurrence Patterns, and Its Corresponding Therapeutic Management after Conversion Therapy Followed by Curative Resection for Hepatocellular Carcinoma: A Real-World Study [0.03%]
新辅助治疗后肝癌治愈性手术的生存结局、复发模式及相应的治疗管理：一项真实世界研究
Rui Xiao,Zhenyun Yang,Zehao Zheng et al.
Rui Xiao et al.
Introduction: There remains a scarcity of research focusing on long-term survival, the administration of adjuvant therapy, and recurrence following conversion resection in patients suffering from initially unresectable he...
Impact of Age on Patient-Reported Outcomes with First-Line Camrelizumab plus Rivoceranib versus Sorafenib in Adults with Unresectable Hepatocellular Carcinoma: Post Hoc Analyses of the CARES-310 Open-Label, Randomized, Phase 3 Trial [0.03%]
卡瑞利珠单抗联合瑞戈非尼一线治疗与索拉非尼治疗不可切除肝细胞癌成人患者的疗效对比：基于年龄因素的事后分析——一项随机、开放性III期研究（CARES-310）
Stephen Lam Chan,Ahmed Omar Kaseb,Laura Alexander et al.
Stephen Lam Chan et al.
Introduction: The CARES-310 randomized, open-label, international phase 3 trial reported improved overall survival and progression-free survival with camrelizumab-rivoceranib compared with sorafenib in adults with unresec...
Multidisciplinary Clinic Approach Improves Immunotherapy Treatment Outcomes in Unresectable Hepatocellular Carcinoma: A Multicentre Retrospective Study [0.03%]
多学科联合门诊可改善不可切除肝细胞癌免疫治疗疗效：一项多中心回顾性研究
Andrea Dalbeni,Alessandra Auriemma,Marco Vicardi et al.
Andrea Dalbeni et al.
Introduction: Given the complexity of managing unresectable hepatocellular carcinoma (HCC), few Italian centres have implemented integrated multidisciplinary clinics (MDTc), where hepatologists and oncologists jointly ass...
Physical Activity Improves Overall Survival in Patients with Hepatocellular Carcinoma [0.03%]
体力活动改善肝细胞癌患者的总体生存率
Byeong Geun Song,Myeongcheol Lee,Juhee Cho et al.
Byeong Geun Song et al.
Introduction: Physical activity improves survival in various cancers, but its impact in patients with hepatocellular carcinoma (HCC) remains unexplored. We aimed to investigate the association between initiating moderate-...
Impact of Procedural Quality on Outcomes of Transarterial Chemoembolization for Hepatocellular Carcinoma: A Multicenter Study [0.03%]
程序质量对肝细胞癌经动脉化疗栓塞治疗结局影响的多中心研究
Nan Jiang,Wen Zhang,Zhenwei Peng et al.
Nan Jiang et al.
Introduction: Transarterial chemoembolization (TACE) is the primary treatment modality for intermediate-stage hepatocellular carcinoma (HCC). However, the lack of standardization to optimal technique leads to a wide varia...